Haisco Enters $140 Million Deal for Osteoarthritis Therapy
September 15, 2021 at 05:49 AM EDT
Haisco Pharmaceutical of Shannan in-licensed China rights to a novel osteoarthritis therapy from San Diego 's Biosplice Therapeutics in a $140 million agreement. Lorecivivint, a potential disease-modifying osteoarthritis drug, is a CLK/DYRK kinase inhibitor that modulates the Wnt pathway. It is currently being tested in a US Phase III trial to treat knee osteoarthritis. Biosplice says it has the potential to be the first novel drug therapy for osteoarthritis in nearly 20 years. Haisco will make $20 million in upfront and near-term milestone payments. More details... Stock Symbol: (SHZ: 002653) Share this with colleagues: // //